VIATRIS INC. Accumulated Other Comprehensive Income
VIATRIS INC. (VTRS) had Accumulated Other Comprehensive Income of -$2.82 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent › Accumulated Other Comprehensive Income (Loss), Net of Tax
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$2.82B.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$2.80B.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$2.71B.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$2.71B.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | -$2.82B 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$2.80B 10-Q · filed 2026-05-07 | |
| 2025-12-31 | -$2.71B 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$2.71B 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$2.66B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | -$2.87B 10-Q · filed 2025-05-08 | |
| 2024-12-31 | -$3.21B 10-Q · filed 2025-11-06 | |
| 2024-09-30 | -$2.69B 10-Q · filed 2024-11-07 | |
| 2024-06-30 | -$2.98B 10-Q · filed 2024-11-07 | |
| 2024-03-31 | -$2.94B 10-Q · filed 2024-08-08 | |
| 2023-12-31 | -$2.75B 10-Q · filed 2024-11-07 | |
| 2023-09-30 | -$3.21B 10-Q · filed 2023-11-08 | |
| 2023-06-30 | -$3.01B 10-Q · filed 2023-11-08 | |
| 2023-03-31 | -$2.76B 10-Q · filed 2023-08-07 | |
| 2022-12-31 | -$2.76B 10-Q · filed 2023-11-08 | |
| 2022-09-30 | -$3.76B 10-Q · filed 2023-11-08 | |
| 2022-06-30 | -$2.90B 10-Q · filed 2023-11-08 | |
| 2022-03-31 | -$2.06B 10-Q · filed 2023-08-07 | |
| 2021-12-31 | -$1.74B 10-K · filed 2023-02-27 | |
| 2021-09-30 | -$1.47B 10-Q · filed 2021-11-08 | |
| 2021-06-30 | -$1.21B 10-Q · filed 2021-11-08 | |
| 2021-03-31 | -$1.39B 10-Q · filed 2021-08-09 | |
| 2020-12-31 | -$858.00M 10-K · filed 2022-02-28 | |
| 2020-09-30 | -$1.42B 10-Q · filed 2021-11-08 | |
| 2020-09-27 | $0.00 10-Q · filed 2020-11-10 | |
| 2020-06-30 | -$2.02B 10-Q · filed 2021-11-08 | |
| 2020-06-28 | $0.00 10-Q · filed 2020-08-12 | |
| 2020-03-31 | -$2.45B 10-Q · filed 2021-08-09 | |
| 2020-03-29 | $0.00 10-Q · filed 2020-05-12 | |
| 2019-12-31 | -$1.80B 10-K · filed 2021-03-01 | $0.00 10-K · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |